Please ensure Javascript is enabled for purposes of website accessibility

Why Karyopharm Therapeutics Inc Shares Are Soaring 31% Today

By Todd Campbell – Aug 30, 2016 at 1:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An approval ahead of key trial data is sparking investor's enthusiasm.

Image source: Stockmonkeys.com via Flickr.

What: After investment research firm Jefferies upgraded the stock to a "buy," shares of Karyopharm Therapeutics Inc. (KPTI 0.61%) have skyrocketed 31.6% at 1:00 p.m. EDT Tuesday.

So What: Karyopharm Therapeutics is a clinical-stage company developing therapies for the treatment of hematological cancers, including multiple myeloma.

The company's most advanced drug is selinexor, which is being evaluated in multiple myeloma, acute myeloid leukemia, diffuse aggressive lymphoma, and other malignancies. Results from its phase 2b clinical trial evaluating selinexor plus low-dose dexamethasone in heavily pretreated multiple myeloma patients is expected later this quarter.

Ahead of that data, Jefferies has boosted its rating on the stock from a "hold" to "buy." Jefferies analysts also set a price target of $12 for Karyopharm Therapeutics shares.

Now What: There's a significant need for new treatment options for heavily pretreated cancer patients, and in previous studies selinexor has shown solid efficacy. In June, a study conducted at the Moffitt Cancer Center showed that six of 10 patients had some level of response to a treatment regimen containing selinexor.

Karyopharm Therapeutics reported in June that 43% of heavily pretreated patients with diffuse large B-cell lymphoma who took selinexor for at least one month showed an overall response rate, too.

If the company's upcoming data is positive, then management plans to approach the FDA to discuss an accelerated approval. Such an approval would be welcome news for investors because the company's cancer operating expenses are clocking in at an annualized $120 million pace.

The multiple myeloma market is worth billions of dollars in sales annually, so an eventual approval could significantly improve the company's financials. It could also spark interest from potential acquirers, and for those reasons Karyopharma Therapeutics is an intriguing, yet high-risk stock.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Karyopharm Therapeutics  Stock Quote
Karyopharm Therapeutics
KPTI
$4.94 (0.61%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.